Potentially inappropriate medications and polypharmacy in the older population: A nationwide cross-sectional study in France in 2019.

Therapie

University Paris-Saclay, UVSQ, University Paris-Sud, Inserm, Anti-infective Evasion and Pharmacoepidemiology, CESP, 78180 Montigny-le-Bretonneux, France; Epidemiology and Public Health Department, Raymond Poincaré Hospital, GHU AP-HP. University of Paris-Saclay, 92380 Garches, France.

Published: November 2023

Aim Of The Study: To assess the prevalence of potentially inappropriate medications (PIMs) and polypharmacy in adults aged 75 years and over in France in 2019 based on data from the French health insurance claims database, at the national level and by region.

Methods: We conducted a cross-sectional study in French adults aged 75 years or over in 2019. We assessed the prevalence of seventeen PIM criteria adapted from the 2015 Beers and STOPP lists, as well as cumulative polypharmacy. Polypharmacy (5 to 9 drugs) and hyper-polypharmacy (≥10 drugs) were defined as the average number of drugs dispensed per quarter. The regional analysis used the age- and sex-standardized prevalence.

Results: Of 6,707,897 older adults, 39.6% were exposed to at least one PIM in 2019, 46.7% were exposed to polypharmacy (5 to 9 drugs), and 25.2% to hyper-polypharmacy (≥10 drugs). Benzodiazepine PIMs were the most frequent (26.9%), followed by atropinic PIMs (8.3%), non-steroidal anti-inflammatory PIMs (7.8%), concomitant use of three or more central nervous system-active drugs (7.3%), and antihypertensive PIMs (6.0%). There was a gradient in the level of exposure to PIMs according to the level of polypharmacy for every PIM category. We observed regional variations in PIM prevalence, from 36.5% in Pays-de-la-Loire to 44.8% in Hauts-de-France in mainland France.

Conclusion: These results show that PIMs concerned more than one in three older adults after age 75 years in France in 2019 and support the need to secure medication use in this population. The reasons for geographic variations in PIM prevalence should be investigated in further studies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.therap.2023.02.001DOI Listing

Publication Analysis

Top Keywords

france 2019
12
inappropriate medications
8
cross-sectional study
8
adults aged
8
aged 75 years
8
75 years france
8
polypharmacy drugs
8
older adults
8
variations pim
8
pim prevalence
8

Similar Publications

Background: Intimate partner violence (IPV) is the most common form of gender-based violence affecting women and girls worldwide and is exacerbated in humanitarian settings. There is evidence that neighborhood social processes influence IPV. Perceived neighborhood social cohesion (P-NSC)-a measure of community trust, attachment, safety, and reciprocity-may be protective against women's experience of and men's perpetration of IPV and controlling behaviors.

View Article and Find Full Text PDF

Introduction: Overcrowding in emergency departments (ED) is a major public health issue, leading to increased workload and exhaustion for the teams, resulting poor outcomes. It seems interesting to be able to predict the admissions of patients in the ED.

Aim: The main objective of this study was to build and test a prediction tool for ED admissions using artificial intelligence.

View Article and Find Full Text PDF

Targeting of diseased cells is one of the most urgently needed prerequisites for a next generation of potent pharmaceuticals. Different approaches pursued fail mainly due to a lack of specific surface markers. Developing an RNA-based methodology, we can now ensure precise cell targeting combined with selective expression of effector proteins for therapy, diagnostics or cell steering.

View Article and Find Full Text PDF

Virological characterization of Parvovirus B19 isolated during the atypical 2023-2024 outbreak in France.

J Infect

January 2025

Microbiology department, Necker-Enfants malades Hospital, AP-HP, Université Paris Cité, Paris, France; Université Paris Cité, URP 7328 FETUS, Paris, France.

Background: A Parvovirus B19 (B19V) outbreak has been reported in Europe in 2023-2024. The aims of this study were 1) to describe the incidence of primary cases from 2012 to 2024 in one French hospital 2) to analyze the genome of 2023 strains 3) to identify virological profiles according to the clinical presentations of B19V infection.

Methods: The incidence of B19V primary cases was studied through an interrupted time-series analysis.

View Article and Find Full Text PDF

Background: Pathologic confirmation of lung cancer influences treatment selection for suspected early-stage lung cancer. High pre-treatment tissue confirmation rates are recommended. We sought to define management and outcomes of patients undergoing surgery for primary lung cancer in a UK multi-centre clinical trial.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!